Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2001-03

AUTHORS

P. Clarke, A. Gray, A. Adler, R. Stevens, M. Raikou, C. Cull, I. Stratton, R. Holman, on behalf of the UKPDS Group

ABSTRACT

AIMS/HYPOTHESIS: To estimate the economic efficiency of intensive blood-glucose control with metformin compared with conventional therapy primarily with diet in overweight patients with Type II (non-insulin-dependent) diabetes mellitus. METHODS: Cost-effectiveness analysis based on patient level data from a randomised clinical controlled trial involving 753 overweight (> 120% ideal body weight) patients with newly diagnosed Type II diabetes conducted in 15 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study. Subjects were allocated at random to an intensive blood-glucose control policy with metformin (n = 342) or a conventional policy primarily with diet (n = 411). The analysis was based on the cost of health care resources associated with metformin and conventional therapy and the estimated effectiveness in terms of life expectancy gained from within-trial effects. RESULTS: Intensive blood-glucose control with metformin produced a net saving of 258 Pounds per patient (1997 United Kingdom prices) over the trial period (median duration of 10.7 years) due to lower complication costs, and increased life expectancy by 0.4 years (costs and benefits discounted at 6%). CONCLUSIONS/INTERPRETATION: As metformin is both cost-saving in the United Kingdom and extends life expectancy when used as first line pharmacological therapy in overweight Type II diabetic patients, its use should be attractive to clinicians and health care managers alike. More... »

PAGES

298-304

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s001250051617

DOI

http://dx.doi.org/10.1007/s001250051617

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001128875

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11317659


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose Self-Monitoring", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Mass Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Costs and Cost Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Sectional Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diet, Diabetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "England", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insulin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metformin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Northern Ireland", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Obesity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Education as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Scotland", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Health Economics Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Headington, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clarke", 
        "givenName": "P.", 
        "id": "sg:person.0734456474.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734456474.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Health Economics Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Headington, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gray", 
        "givenName": "A.", 
        "id": "sg:person.01307325071.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307325071.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adler", 
        "givenName": "A.", 
        "id": "sg:person.01327503373.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327503373.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stevens", 
        "givenName": "R.", 
        "id": "sg:person.01052527755.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052527755.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "City, University of London", 
          "id": "https://www.grid.ac/institutes/grid.28577.3f", 
          "name": [
            "Department of Economics, City University, London, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raikou", 
        "givenName": "M.", 
        "id": "sg:person.0720431761.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720431761.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cull", 
        "givenName": "C.", 
        "id": "sg:person.0637007241.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637007241.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stratton", 
        "givenName": "I.", 
        "id": "sg:person.01201354332.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201354332.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holman", 
        "givenName": "R.", 
        "id": "sg:person.01017043005.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017043005.08"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "on behalf of the UKPDS Group", 
        "type": "Person"
      }
    ], 
    "datePublished": "2001-03", 
    "datePublishedReg": "2001-03-01", 
    "description": "AIMS/HYPOTHESIS: To estimate the economic efficiency of intensive blood-glucose control with metformin compared with conventional therapy primarily with diet in overweight patients with Type II (non-insulin-dependent) diabetes mellitus.\nMETHODS: Cost-effectiveness analysis based on patient level data from a randomised clinical controlled trial involving 753 overweight (> 120% ideal body weight) patients with newly diagnosed Type II diabetes conducted in 15 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study. Subjects were allocated at random to an intensive blood-glucose control policy with metformin (n = 342) or a conventional policy primarily with diet (n = 411). The analysis was based on the cost of health care resources associated with metformin and conventional therapy and the estimated effectiveness in terms of life expectancy gained from within-trial effects.\nRESULTS: Intensive blood-glucose control with metformin produced a net saving of 258 Pounds per patient (1997 United Kingdom prices) over the trial period (median duration of 10.7 years) due to lower complication costs, and increased life expectancy by 0.4 years (costs and benefits discounted at 6%).\nCONCLUSIONS/INTERPRETATION: As metformin is both cost-saving in the United Kingdom and extends life expectancy when used as first line pharmacological therapy in overweight Type II diabetic patients, its use should be attractive to clinicians and health care managers alike.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s001250051617", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "name": "Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51)", 
    "pagination": "298-304", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "0560eb21de7c953378d71f1e0dfd8e5f6660960b6b1728dfd825aee05446aee8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11317659"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0006777"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s001250051617"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001128875"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s001250051617", 
      "https://app.dimensions.ai/details/publication/pub.1001128875"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89822_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs001250051617"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s001250051617'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s001250051617'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s001250051617'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s001250051617'


 

This table displays all metadata directly associated to this object as RDF triples.

222 TRIPLES      20 PREDICATES      53 URIs      45 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s001250051617 schema:about N17b850a649244ca3b864df454be912fb
2 N1fde75b67a7c45a1a9cb1f46461cf8fb
3 N22eea3886db146329983113416c80577
4 N2fb3d0af9df341d893da8582994f1e3a
5 N3e9d787317954c858585da19995e8cbb
6 N4108fe21e43b45f9857f60bc330242f4
7 N441c66de32f84c5aab7a6eb66ef4230c
8 N448d314fa2694c5e8d5b71be82088e77
9 N50575b077c6246feb572d93191b06cac
10 N5177b15520d04657a9c2d7a25c29d2f2
11 N5bb62729450b4200aa874f6a021db55c
12 N5c1cd50ab5e34be1ad5ebc6159babc9e
13 N67f2bbb98d7e49718e384e9890b6e308
14 N7412afec72134e0dbcaefe2d7914cd29
15 N7adbfa9f4d7d4bbd875f2ba5c5b3d0f4
16 N909b945add6b47129892718f9247d06c
17 Na26944ef4bb04c9a97451ad10a76e50d
18 Na54b075bcdce480d8b3665232c580b62
19 Naf10f9a769c248d889c20d8518836192
20 Nb2fca4325b7f4bc39b58ea43050fc640
21 Ncf5f928c5f0a4f5ea5ec13d9fbd869e2
22 Ndb9ddef034e34db894003d42bccd22ce
23 Ndbb186e5587b47f0ad51e1162b9537d8
24 Nf735926431f14da595559b7204b131e7
25 anzsrc-for:11
26 anzsrc-for:1103
27 schema:author N513adf03f2e14bc59f5a05b51425a804
28 schema:datePublished 2001-03
29 schema:datePublishedReg 2001-03-01
30 schema:description AIMS/HYPOTHESIS: To estimate the economic efficiency of intensive blood-glucose control with metformin compared with conventional therapy primarily with diet in overweight patients with Type II (non-insulin-dependent) diabetes mellitus. METHODS: Cost-effectiveness analysis based on patient level data from a randomised clinical controlled trial involving 753 overweight (> 120% ideal body weight) patients with newly diagnosed Type II diabetes conducted in 15 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study. Subjects were allocated at random to an intensive blood-glucose control policy with metformin (n = 342) or a conventional policy primarily with diet (n = 411). The analysis was based on the cost of health care resources associated with metformin and conventional therapy and the estimated effectiveness in terms of life expectancy gained from within-trial effects. RESULTS: Intensive blood-glucose control with metformin produced a net saving of 258 Pounds per patient (1997 United Kingdom prices) over the trial period (median duration of 10.7 years) due to lower complication costs, and increased life expectancy by 0.4 years (costs and benefits discounted at 6%). CONCLUSIONS/INTERPRETATION: As metformin is both cost-saving in the United Kingdom and extends life expectancy when used as first line pharmacological therapy in overweight Type II diabetic patients, its use should be attractive to clinicians and health care managers alike.
31 schema:genre research_article
32 schema:inLanguage en
33 schema:isAccessibleForFree true
34 schema:isPartOf Nb047154a2ec4463cae0d46c277c37e50
35 Nf66a305818d840029f0d9fff43472e5b
36 sg:journal.1001482
37 schema:name Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51)
38 schema:pagination 298-304
39 schema:productId N5e74a5ba6fc449d5bc96893b76b19e4d
40 N60bffca919cd40a7827569c89a3841fc
41 N81dd8a6f98f24f04bedf3d7b7a623fca
42 Nbdd19d1a9f1e4b0ab6a7c42e1893f099
43 Neaeed7f03c294310902897db7cf069ca
44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001128875
45 https://doi.org/10.1007/s001250051617
46 schema:sdDatePublished 2019-04-11T10:02
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher N4f3ec1f081d64e53b3c54dec9b4628aa
49 schema:url https://link.springer.com/10.1007%2Fs001250051617
50 sgo:license sg:explorer/license/
51 sgo:sdDataset articles
52 rdf:type schema:ScholarlyArticle
53 N0341e8c70254454cb71bbec56eedeafd rdf:first N45775a4b4cc84b70846090efac6c3393
54 rdf:rest rdf:nil
55 N0d642c4f46c54dbe936872475a18d566 rdf:first sg:person.01307325071.02
56 rdf:rest N337927dfb380456ab4c635cdf347e1a0
57 N17b850a649244ca3b864df454be912fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name United Kingdom
59 rdf:type schema:DefinedTerm
60 N1fde75b67a7c45a1a9cb1f46461cf8fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Antihypertensive Agents
62 rdf:type schema:DefinedTerm
63 N22eea3886db146329983113416c80577 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Blood Glucose Self-Monitoring
65 rdf:type schema:DefinedTerm
66 N2c8db819fe054ee8b2530652bf887b8e rdf:first sg:person.0637007241.52
67 rdf:rest N5e86b21e66ad46a0bc5e38d2134eb29e
68 N2fb3d0af9df341d893da8582994f1e3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name England
70 rdf:type schema:DefinedTerm
71 N337927dfb380456ab4c635cdf347e1a0 rdf:first sg:person.01327503373.58
72 rdf:rest N4ee0a0b147ac417bb78ee7c225b5e594
73 N3e9d787317954c858585da19995e8cbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Northern Ireland
75 rdf:type schema:DefinedTerm
76 N4108fe21e43b45f9857f60bc330242f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Humans
78 rdf:type schema:DefinedTerm
79 N441c66de32f84c5aab7a6eb66ef4230c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Aged
81 rdf:type schema:DefinedTerm
82 N448d314fa2694c5e8d5b71be82088e77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Diabetes Mellitus
84 rdf:type schema:DefinedTerm
85 N45775a4b4cc84b70846090efac6c3393 schema:familyName on behalf of the UKPDS Group
86 rdf:type schema:Person
87 N4ee0a0b147ac417bb78ee7c225b5e594 rdf:first sg:person.01052527755.23
88 rdf:rest Nf4f15afced184938b8ad2eef38c98eb5
89 N4f3ec1f081d64e53b3c54dec9b4628aa schema:name Springer Nature - SN SciGraph project
90 rdf:type schema:Organization
91 N50575b077c6246feb572d93191b06cac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Cost-Benefit Analysis
93 rdf:type schema:DefinedTerm
94 N513adf03f2e14bc59f5a05b51425a804 rdf:first sg:person.0734456474.38
95 rdf:rest N0d642c4f46c54dbe936872475a18d566
96 N5177b15520d04657a9c2d7a25c29d2f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Blood Glucose
98 rdf:type schema:DefinedTerm
99 N5bb62729450b4200aa874f6a021db55c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Diet, Diabetic
101 rdf:type schema:DefinedTerm
102 N5c1cd50ab5e34be1ad5ebc6159babc9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Scotland
104 rdf:type schema:DefinedTerm
105 N5e74a5ba6fc449d5bc96893b76b19e4d schema:name readcube_id
106 schema:value 0560eb21de7c953378d71f1e0dfd8e5f6660960b6b1728dfd825aee05446aee8
107 rdf:type schema:PropertyValue
108 N5e86b21e66ad46a0bc5e38d2134eb29e rdf:first sg:person.01201354332.66
109 rdf:rest Nb66acb68efb44e59ae14061780cd12b5
110 N60bffca919cd40a7827569c89a3841fc schema:name pubmed_id
111 schema:value 11317659
112 rdf:type schema:PropertyValue
113 N67f2bbb98d7e49718e384e9890b6e308 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Hypertension
115 rdf:type schema:DefinedTerm
116 N7412afec72134e0dbcaefe2d7914cd29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Adult
118 rdf:type schema:DefinedTerm
119 N7adbfa9f4d7d4bbd875f2ba5c5b3d0f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Patient Education as Topic
121 rdf:type schema:DefinedTerm
122 N81dd8a6f98f24f04bedf3d7b7a623fca schema:name nlm_unique_id
123 schema:value 0006777
124 rdf:type schema:PropertyValue
125 N909b945add6b47129892718f9247d06c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Insulin
127 rdf:type schema:DefinedTerm
128 Na26944ef4bb04c9a97451ad10a76e50d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Diabetes Mellitus, Type 2
130 rdf:type schema:DefinedTerm
131 Na54b075bcdce480d8b3665232c580b62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Costs and Cost Analysis
133 rdf:type schema:DefinedTerm
134 Naf10f9a769c248d889c20d8518836192 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Metformin
136 rdf:type schema:DefinedTerm
137 Nb047154a2ec4463cae0d46c277c37e50 schema:issueNumber 3
138 rdf:type schema:PublicationIssue
139 Nb2fca4325b7f4bc39b58ea43050fc640 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Middle Aged
141 rdf:type schema:DefinedTerm
142 Nb66acb68efb44e59ae14061780cd12b5 rdf:first sg:person.01017043005.08
143 rdf:rest N0341e8c70254454cb71bbec56eedeafd
144 Nbdd19d1a9f1e4b0ab6a7c42e1893f099 schema:name dimensions_id
145 schema:value pub.1001128875
146 rdf:type schema:PropertyValue
147 Ncf5f928c5f0a4f5ea5ec13d9fbd869e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Cross-Sectional Studies
149 rdf:type schema:DefinedTerm
150 Ndb9ddef034e34db894003d42bccd22ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Obesity
152 rdf:type schema:DefinedTerm
153 Ndbb186e5587b47f0ad51e1162b9537d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Body Mass Index
155 rdf:type schema:DefinedTerm
156 Neaeed7f03c294310902897db7cf069ca schema:name doi
157 schema:value 10.1007/s001250051617
158 rdf:type schema:PropertyValue
159 Nf4f15afced184938b8ad2eef38c98eb5 rdf:first sg:person.0720431761.48
160 rdf:rest N2c8db819fe054ee8b2530652bf887b8e
161 Nf66a305818d840029f0d9fff43472e5b schema:volumeNumber 44
162 rdf:type schema:PublicationVolume
163 Nf735926431f14da595559b7204b131e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Hypoglycemic Agents
165 rdf:type schema:DefinedTerm
166 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
167 schema:name Medical and Health Sciences
168 rdf:type schema:DefinedTerm
169 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
170 schema:name Clinical Sciences
171 rdf:type schema:DefinedTerm
172 sg:journal.1001482 schema:issn 0012-186X
173 1432-0428
174 schema:name Diabetologia
175 rdf:type schema:Periodical
176 sg:person.01017043005.08 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
177 schema:familyName Holman
178 schema:givenName R.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017043005.08
180 rdf:type schema:Person
181 sg:person.01052527755.23 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
182 schema:familyName Stevens
183 schema:givenName R.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052527755.23
185 rdf:type schema:Person
186 sg:person.01201354332.66 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
187 schema:familyName Stratton
188 schema:givenName I.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201354332.66
190 rdf:type schema:Person
191 sg:person.01307325071.02 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
192 schema:familyName Gray
193 schema:givenName A.
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307325071.02
195 rdf:type schema:Person
196 sg:person.01327503373.58 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
197 schema:familyName Adler
198 schema:givenName A.
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327503373.58
200 rdf:type schema:Person
201 sg:person.0637007241.52 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
202 schema:familyName Cull
203 schema:givenName C.
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637007241.52
205 rdf:type schema:Person
206 sg:person.0720431761.48 schema:affiliation https://www.grid.ac/institutes/grid.28577.3f
207 schema:familyName Raikou
208 schema:givenName M.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720431761.48
210 rdf:type schema:Person
211 sg:person.0734456474.38 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
212 schema:familyName Clarke
213 schema:givenName P.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734456474.38
215 rdf:type schema:Person
216 https://www.grid.ac/institutes/grid.28577.3f schema:alternateName City, University of London
217 schema:name Department of Economics, City University, London, UK, GB
218 rdf:type schema:Organization
219 https://www.grid.ac/institutes/grid.4991.5 schema:alternateName University of Oxford
220 schema:name Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB
221 Health Economics Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Headington, Oxford, UK, GB
222 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...